Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration

NCTID	NCT05657301 (View at clinicaltrials.gov)
Description	VAN-2201 is Phase I clinical trial to assess the safety and tolerability of KH631 in subjects with neovascular AMD. KH631 is gene therapy designed to deliver a protein which targets and blocks VEGF via an adeno-associated viral vector. The standard of care for patients with neovascular AMD are anti-VEGF treaments, which have demonstrated improvement in vision and reduction in fluid. A one time placement of a product which inhibits VEGF has the potential to reduce the patient burden of regular intraocular injections. (Show More)
Development Status	Active
Indication	Neovascular (Wet) Age-Related Macular Degeneration (nAMD)
Disease Ontology Term	DOID:10871
Compound Name	KH631
Sponsor	Chengdu Origen Biotechnology Co., Ltd.
Funder Type	Industry
Recruitment Status	Recruiting
Enrollment Count	25
Results Posted	Not Available

Target Gene/Variant	VEGFR1/R2 fusion protein
Therapy Type	Gene transfer
Therapy Route	In-vivo
Mechanism of Action	Genetic delivery of therapeutic protein
Route of Administration	Intravitreal
Drug Product Type	Viral vector
Target Tissue/Cell
Delivery System	Viral transduction
Vector Type	AAV8
Editor Type	none
Dose 1	5 undisclosed dose levels (200ul/dose)
Dose 2
Dose 3
Dose 4
Dose 5

No.of Trial Sites	7
Locations	United States